Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 14/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | CA4 | P22748 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046381 | 0.93 | PTGER2 (0.82) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276293 | 0.91 | PTGER2 (0.85) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6276340 | 0.89 | PTGER2 (0.65) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6281961 | 0.87 | PTGER2 (0.67) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5046833 | 0.87 | PTGER2 (0.66) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5049408 | 0.86 | PTGER2 (0.65) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5043167 | 0.84 | PTGER2 (0.64) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5046418 | 0.84 | PTGER2 (0.62) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL5140001 | 0.84 | PTGER2 (0.81) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL1147570 | 0.83 | PTGER2 (0.81) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852863-B2 | Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | CAMERON KIMBERLY O (US) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216445-A1 | Metabolites of (3-[[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid | ABAT, BCAT2, PC | PTGER2 3715/4885CA12 2546/4885CA1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.